• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kamada Ltd.

    3/5/25 12:46:58 PM ET
    $KMDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KMDA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    Kamada Ltd.

    (Name of Issuer)


    Ordinary Shares, par value NIS 1.0 per share

    (Title of Class of Securities)


    M6240T109

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    M6240T109


    1Names of Reporting Persons

    Gov Financial Holdings Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,455,459.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,455,459.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,455,459.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.53 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  * Gov Financial Holdings Ltd. ("Gov") is wholly-owned by Mr. Leon Recanati, who exercises sole voting and investment power over the shares held by Gov. ** Calculated based on 57,505,031 ordinary shares of the Issuer outstanding as of December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    M6240T109


    1Names of Reporting Persons

    Insight Capital Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,346,335.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,346,335.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,346,335.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.34 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  * Insight Capital Ltd. ("Insight") is wholly-owned by Mr. Leon Recanati, who exercises sole voting and investment power over the shares held by Insight. ** Calculated based on 57,505,031 ordinary shares of the Issuer outstanding as of December 31, 2024.


    SCHEDULE 13G

    CUSIP No.
    M6240T109


    1Names of Reporting Persons

    Leon Recanati
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ISRAEL
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    687,645.00
    6Shared Voting Power

    2,801,794.00
    7Sole Dispositive Power

    687,645.00
    8Shared Dispositive Power

    2,801,794.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,489,439.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.07 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  * Mr. Recanati directly holds 631,145 ordinary shares of the Issuer and options to purchase 56,500 ordinary shares of the Issuer currently exercisable or exercisable within 60 days of December 31, 2024. In addition, Mr. Recanati beneficially owns 1,455,459 ordinary shares of the Issuer through Gov and 1,346,335 ordinary shares of the Issuer through Insight, both of which are wholly-owned by Mr. Leon Recanati. ** Calculated based on 57,505,031 ordinary shares of the Issuer outstanding as of December 31, 2024.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Kamada Ltd.
    (b)Address of issuer's principal executive offices:

    2 Holzman St., Science Park, P.O. Box 4081, Rehovot, 7670402, Israel
    Item 2. 
    (a)Name of person filing:

    Gov Financial Holdings Ltd. Insight Capital Ltd. Leon Recanati
    (b)Address or principal business office or, if none, residence:

    27 Yoav St. 69081, Israel
    (c)Citizenship:

    Israel
    (d)Title of class of securities:

    Ordinary Shares, par value NIS 1.0 per share
    (e)CUSIP No.:

    M6240T109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Gov Financial Holdings Ltd. 1,455,459 Ordinary Shares Insight Capital Ltd. 1,346,335 Leon Recanati 3,489,439 Ordinary Shares
    (b)Percent of class:

    Gov Financial Holdings Ltd. 2.53%* Insight Capital Ltd. 2.34%* Leon Recanati 6.07%* * Calculated based on 57,505,031 ordinary shares of the Issuer outstanding as of December 31, 2024.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Item 5 of each cover page.

     (ii) Shared power to vote or to direct the vote:

    See Item 6 of each cover page.

     (iii) Sole power to dispose or to direct the disposition of:

    See Item 7 of each cover page.

     (iv) Shared power to dispose or to direct the disposition of:

    See Item 8 of each cover page. * Calculations are based on 57,505,031 Ordinary Shares of the Issuer outstanding as of December 31, 2024.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Gov Financial Holdings Ltd.
     
    Signature:/s/ Leon Recanati
    Name/Title:Leon Recanati/Chairman and CEO
    Date:03/05/2025
     
    Insight Capital Ltd.
     
    Signature:/s/ Leon Recanati
    Name/Title:Leon Recanati/Chairman and CEO
    Date:03/05/2025
     
    Leon Recanati
     
    Signature:/s/ Leon Recanati
    Name/Title:Leon Recanati
    Date:03/05/2025
    Exhibit Information

    Exhibit 99.1 Joint Filing Agreement, dated March 5, 2025

    Get the next $KMDA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KMDA

    DatePrice TargetRatingAnalyst
    3/21/2025$15.00Buy
    The Benchmark Company
    7/3/2024$18.00Buy
    Stifel
    More analyst ratings

    $KMDA
    Leadership Updates

    Live Leadership Updates

    See more
    • Kamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity Funds

      Funding Strengthens Kamada's Financial Position, Supporting its Growth Plans and the Pursuit of Strategic Business Development OpportunitiesAppointment of Two New Independent Directors to its Board: Professor Benjamin Dekel and Mr. Assaf Itshayek REHOVOT, Israel and HOBOKEN, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced shareholder approval and planned closing of the previously announced $60 million private placement (the "Private Placement") with FIMI Op

      8/30/23 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

      REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA))) ("Kamada" or the "Company"), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that following the recently announced $60 million private placement with the FIMI Opportunity Funds, which is expected to contribute to accelerating the growth of its existing business and allow the Company to pursue compelling business development opportunities, Chief Financial Officer (CFO), Chaime Orlev, who had previously planned to transition out of h

      5/24/23 7:05:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMDA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

      Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, TexasLaunched Comprehensive Post-Marketing Research Program of CYTOGAM®Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growth Year-over-Year Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharm

      5/14/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

      REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14, 2025. Kamada management will host an investment community conference call on Wednesday, May 14, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in

      5/7/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

      Program Aimed at Generating Key Data in Support of the Benefits of CYTOGAM® in the Management of Cytomegalovirus (CMV) in Solid Organ TransplantationA Total of 10 Studies will be Conducted in Collaboration with Leading U.S. Physicians, Primarily as Investigator-Initiated Studies (IIS)Results of the Planned Studies are Expected to be Published and/or Presented in Peer Reviewed Industry Journals and Medical Meetings in the Coming Years REHOVOT, Israel, and HOBOKEN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty

      5/5/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $KMDA
    SEC Filings

    See more
    • Amendment: SEC Form SC 13G/A filed by Kamada Ltd.

      SC 13G/A - KAMADA LTD (0001567529) (Subject)

      11/14/24 6:21:51 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

      SC 13G/A - KAMADA LTD (0001567529) (Subject)

      2/14/24 5:04:02 PM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kamada Ltd. (Amendment)

      SC 13G/A - KAMADA LTD (0001567529) (Subject)

      2/12/24 12:41:57 PM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Kamada Ltd.

      6-K - KAMADA LTD (0001567529) (Filer)

      5/14/25 7:00:26 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Kamada Ltd.

      6-K - KAMADA LTD (0001567529) (Filer)

      5/7/25 7:07:41 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Kamada Ltd.

      6-K - KAMADA LTD (0001567529) (Filer)

      5/5/25 7:00:24 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMDA
    Financials

    Live finance-specific insights

    See more
    • Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

      Revenues for First Quarter of 2025 of $44.0 Million, Representing a 17% Year-over-Year IncreaseFirst Quarter Adjusted EBITDA of $11.6 Million, Up 54% Year-over-YearStrong Financial Position to Accelerate Growth Through M&A and/or In-licensing Opportunities Announced Expansion of Plasma Collection Operations with Opening of New Site in San Antonio, TexasLaunched Comprehensive Post-Marketing Research Program of CYTOGAM®Reiterating Full Year 2025 Guidance, Representing Double Digit Profitable Growth Year-over-Year Conference Call and Live Webcast Today at 8:30am ET REHOVOT, Israel and HOBOKEN, N.J., May 14, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharm

      5/14/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

      REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14, 2025. Kamada management will host an investment community conference call on Wednesday, May 14, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in

      5/7/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

      REHOVOT, Israel and HOBOKEN, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ:KMDA, TASE: KMDA.TA)), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, announced today that it has obtained a tax ruling (the "Ruling") from the Israel Tax Authority (the "ITA") with respect to the special cash dividend of $0.20 (approximately NIS 0.72) per share on the Company's ordinary shares (totaling approximately $11.5 million) announced on March 5, 2025 (the "Dividend"), expected to be paid on April 7, 2025 (the "Payment Date"), to shareholders of record at the close of busines

      3/24/25 7:00:00 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on Kamada with a new price target

      The Benchmark Company initiated coverage of Kamada with a rating of Buy and set a new price target of $15.00

      3/21/25 8:11:15 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Kamada with a new price target

      Stifel initiated coverage of Kamada with a rating of Buy and set a new price target of $18.00

      7/3/24 7:31:15 AM ET
      $KMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care